RAPP Stock Forecast & Price Target

Rapport Therapeutics is attractive because RAP-219 has already shown unusually strong phase 2a focal-onset seizure data, including a 77.8% median seizure reduction, 24% seizure freedom, and only 10% treatment-emergent discontinuation in a difficult-to-treat population. Its TARPγ8-selective, forebrain-restricted AMPA modulation offers a differentiated mechanism that may preserve efficacy while avoiding the psychiatric and tolerability liabilities seen with broader AMPA blockade, supporting confidence in the ongoing phase 3 epilepsy program initiated in 2Q26. The company also has meaningful upside optionality in bipolar mania and discovery-stage nAChR programs, while a $436 million cash position into 2H29 provides financial runway to advance multiple catalysts.

Rapport Therapeutics is exposed to a fragile investment case because its lead mania thesis rests on an inferred mechanism, while no AMPA-NAM has yet shown randomized antimanic efficacy and the class carries a real psychiatric safety headwind. The stock’s sharp run-up from $42.44 to $52.50 ahead of the readout, followed by a drop to $34.13, suggests mania is only optionality rather than a core value driver, limiting upside while leaving meaningful downside if the October readout disappoints. Fundamentally, the company also faces financing risk until cash-flow positive, third-party manufacturing dependence, and stiff competition in epilepsy and bipolar markets, while FOS still depends on 30%-40% refractory patients and clinical proof that has not yet been established.